Evidence map›Paper›PMID 39702688›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Preclinical study of TLR stimulation combined PD-1 antibody enhance the therapeutic effect of microwave ablation on NSCLC.

Ying Yu, Fu Niu, Bo Sun, Shusen Zhang, Zhigang Cai

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. [Progress in the Immune Mechanism of Microwave Ablation Therapy for Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ying Yu *Hebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Fu Niu *Hebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Bo SunHebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Shusen ZhangHebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Zhigang CaiHebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China. zhigang_cai@hebmu.edu.cn.ORCID http://orcid.org/0000-0002-2190-4928

Funding

Natural Science Foundation of Hebei Province No. H2021108003
6 · The paper itself

Abstract

purposeThe purpose of this study was to investigate the therapeutic efficacy of the combination of microwave ablation (MWA) with immune checkpoints blockade and TLR9 stimulation in the treatment of non-small cell lung cancer (NSCLC) using the C57BL/6 tumor-bearing mice model. MATERIALS AND

methodsTumor-bearing mice were treated with MWA, programmed cell death protein1 blockade (PD-1) plus MWA (MWA + P), TLR9 agonist CpG ODNs and MWA (MWA + C), PD-1 blockade and CpG ODNs (P + C), MWA plus PD-1 blockade and CpG ODNs (MWA + P + C), or untreated. Survival time was evaluated with the Kaplan-Meyer method comparing survival curves by log-rank test. On day 15 after MWA, ten mice from the combination therapy group received tumor rechallenge with LLC cells and the volumes of rechallenge tumor were calculated every 5 days. Immune cells were identified by immunohistochemistry and flow cytometry, and the concentrations of IFN-γ、TNF-α and TGF-β were identified by enzyme-linked immunosorbent assay (ELISA).

resultsThe MWA + P + C combination therapy significantly prolonged tumor-bearing mice survival and reduced tumor size compared to untreated group, MWA group, MWA + P group, M + C group, P + C group. The combination therapy also protected most surviving mice from LLC tumor rechallenge. CD8 + T-cell in tumor and spleen were remarkably induced by MWA + P + C and Treg cell further diminished by combination therapy. Both tumor necrosis factor-alpha (TNF-α) and interferon-gama (IFN-γ) concentrations in plasma were significantly elevated in the combination therapy group compared to other groups, while transforming growth factor Beta (TGF-β) was reduced.

conclusionMWA combined with immune checkpoints blockade and TLR stimulation could significantly enhance antitumor efficacy with augmented specific immune responses, and the combination therapy is a promising approach to treat non-small cell lung cancer (NSCLC).

Indexed as

Ablation TechniquesCarcinoma, Lewis LungCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsMicrowavesProgrammed Cell Death 1 ReceptorToll-Like Receptor 9AnimalsCombined Modality TherapyFemaleMiceMice, Inbred C57BLOligodeoxyribonucleotidesCPG-oligonucleotideImmune Checkpoint InhibitorsOligodeoxyribonucleotidesPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorTlr9 protein, mouseToll-Like Receptor 9Cell immunotherapyCombination therapyMicrowave ablationNon-small cell lung cancerNonspecific immunity

Identifiers

PMID39702688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.